Elranatamab

Phase 2Recruiting

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Smoldering Multiple Myeloma

Conditions

Smoldering Multiple Myeloma

Trial Timeline

May 14, 2024 → Jul 1, 2031

NCT ID

NCT06183489

About Elranatamab

Elranatamab is a phase 2 stage product being developed by Pfizer for Smoldering Multiple Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06183489. Target conditions include Smoldering Multiple Myeloma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05238311	Pre-clinical	Completed	—	—	Multiple Myeloma
NCT07382739	Phase 2	Recruiting	Jul 14, 2026	Dec 31, 2030	Phase 2
NCT07320326	Pre-clinical	Recruiting	Dec 30, 2025	Sep 18, 2028	TCE-RRMM
NCT06581848	Pre-clinical	Active	Jun 5, 2025	Jan 31, 2030	Multiple Myeloma
NCT06947083	Phase 2	Recruiting	May 27, 2025	Apr 1, 2029	Myeloma
NCT06015542	Phase 2	Recruiting	Jan 29, 2025	Jul 1, 2027	Multiple Myeloma
NCT06183489	Phase 2	Recruiting	May 14, 2024	Jul 1, 2031	Smoldering Multiple Myeloma
NCT06138275	Phase 2	Recruiting	Mar 8, 2024	Dec 1, 2028	Refractory Multiple Myeloma
NCT06057402	Approved	Recruiting	Oct 3, 2023	Feb 22, 2032	Multiple Myeloma
NCT05228470	Phase 2	Completed	Dec 21, 2021	Sep 11, 2025	Elranatamab
NCT05014412	Phase 2	Completed	Oct 7, 2021	Dec 12, 2025	Multiple Myeloma

Competing Products

13 competing products in Smoldering Multiple Myeloma

See all competitors

Product	Company	Stage	Hype Score
Elotuzumab (BMS-901608; HuLuc63)	AbbVie	Phase 2	52
BHQ880	Novartis	Phase 2	52
carfilzomib + Lenalidomide + Dexamethasone + Melphalan	Amgen	Phase 2	51
Denosumab	Amgen	Phase 2	51
Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone	Amgen	Phase 2	51
Nivolumab + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 2	51
Elotuzumab + Lenalidomide + Dexamethasone	Bristol Myers Squibb	Phase 2	51
Dexamethasone + Iberdomide Hydrochloride	Bristol Myers Squibb	Phase 2	51
Linvoseltamab	Regeneron Pharmaceuticals	Phase 2	51
Linvoseltamab + Daratumumab	Regeneron Pharmaceuticals	Phase 3	76
Selinexor	Karyopharm Therapeutics	Phase 2	44
IPH2101	Innate Pharma	Phase 2	44
PD-L1 peptide	IO Biotech	Phase 2	44

Other Products from Pfizer